Company: LIMN
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001104659-25-010605
Chunk: 195

Company: Liminatus Pharma, Inc.
Filing Date: 2025-02-07
Form: 424B3
Chunk 195
---
 common stock owned by certain Liminatus Members, the PIPE Investor, the Sponsor, and Cantor Fitzgerald & Co. or their transferees will be subject to the Registration Rights Agreement that provides for the registration for resale of ParentCo’s common stock held by the parties to the Registration Rights Agreement or their transferees. The parties to the Registration Rights Agreement are expected to own approximately 72% of ParentCo’s common stock following the closing of the Business Combination assuming no redemptions. Sales of securities pursuant to this agreement may substantially depress the market price of ParentCo’s common stock.

In connection with the PIPE Equity Investment, ParentCo will grant the PIPE Investor certain customary registration rights as described under “Registration Rights Agreement”.

Each of Iris and Liminatus have incurred and will incur substantial costs in connection with the Business Combination and related transactions, such as legal, accounting, consulting and financial advisory fees.

Each of Iris and Liminatus have incurred and expect that it will incur significant, non-recurring costs in connection with consummating the Business Combination. Iris and Liminatus may also incur additional costs to retain key employees. Iris and Liminatus will also incur significant legal, financial advisor, accounting, banking and consulting fees, fees relating to regulatory filings and notices, SEC filing fees, printing and mailing fees and other costs associated with the Business Combination. Although the parties have been provided with estimates of the costs for each advisory firm, the total actual costs may exceed those estimates and some of these costs are payable regardless of whether the Business Combination are completed.

While Iris and Liminatus work to complete the Business Combination, management’s focus and resources may be diverted from operational matters and other strategic opportunities.

Successful completion of the Business Combination may place a significant burden on the management of Iris and Liminatus and other internal resources. The diversion of management’s attention and any difficulties encountered in the transition process could harm ParentCo’s business, financial condition, results of operations and prospects, including with respect to any future growth-oriented acquisitions undertaken by ParentCo. Diversion of management’s attention and any difficulties encountered in the transition process could have an adverse effect on ParentCo.

Following the consummation of the Business Combination, ParentCo will incur significant increased expenses and administrative burdens as a public company, which could have an adverse effect on its business, financial condition and results of operations.

Following the consummation of the Business Combination, ParentCo will face increased legal, accounting, administrative and other costs and expenses as a public company that Liminatus does not